Wrapmanager Inc. boosted its stake in Merck & Co., Inc. (NYSE:MRK – Free Report) by 19.1% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,758 shares of the company’s stock after purchasing an additional 1,086 shares during the quarter. Wrapmanager Inc.’s holdings in Merck & Co., Inc. were worth $767,000 as of its most recent SEC filing.
Other hedge funds have also bought and sold shares of the company. AM Squared Ltd purchased a new stake in shares of Merck & Co., Inc. during the 3rd quarter valued at about $34,000. Peterson Financial Group Inc. purchased a new stake in shares of Merck & Co., Inc. during the 3rd quarter valued at about $36,000. Itau Unibanco Holding S.A. bought a new position in Merck & Co., Inc. during the 2nd quarter valued at about $39,000. Abich Financial Wealth Management LLC grew its holdings in Merck & Co., Inc. by 121.8% during the 2nd quarter. Abich Financial Wealth Management LLC now owns 326 shares of the company’s stock valued at $40,000 after purchasing an additional 179 shares during the last quarter. Finally, Quarry LP bought a new position in Merck & Co., Inc. during the 2nd quarter valued at about $42,000. Hedge funds and other institutional investors own 76.07% of the company’s stock.
Wall Street Analyst Weigh In
Several equities analysts recently commented on MRK shares. Daiwa Capital Markets downgraded shares of Merck & Co., Inc. from a “buy” rating to a “neutral” rating in a report on Monday, November 11th. Sanford C. Bernstein started coverage on shares of Merck & Co., Inc. in a report on Thursday, October 17th. They set a “market perform” rating and a $115.00 price target on the stock. Truist Financial cut their price target on shares of Merck & Co., Inc. from $132.00 to $130.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. Bank of America cut their price target on shares of Merck & Co., Inc. from $150.00 to $145.00 and set a “buy” rating on the stock in a report on Wednesday, July 31st. Finally, Wolfe Research started coverage on shares of Merck & Co., Inc. in a report on Friday. They set a “peer perform” rating on the stock. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, ten have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $130.86.
Merck & Co., Inc. Trading Up 0.3 %
NYSE:MRK opened at $96.56 on Tuesday. Merck & Co., Inc. has a 52 week low of $94.48 and a 52 week high of $134.63. The firm has a 50 day moving average of $108.46 and a 200 day moving average of $118.60. The company has a quick ratio of 1.15, a current ratio of 1.36 and a debt-to-equity ratio of 0.79. The stock has a market capitalization of $244.26 billion, a price-to-earnings ratio of 20.24, a PEG ratio of 1.38 and a beta of 0.40.
Merck & Co., Inc. (NYSE:MRK – Get Free Report) last posted its earnings results on Thursday, October 31st. The company reported $1.57 EPS for the quarter, beating analysts’ consensus estimates of $1.50 by $0.07. Merck & Co., Inc. had a net margin of 19.23% and a return on equity of 36.42%. The company had revenue of $16.66 billion during the quarter, compared to analysts’ expectations of $16.47 billion. During the same quarter in the prior year, the company posted $2.13 earnings per share. Merck & Co., Inc.’s revenue for the quarter was up 4.4% compared to the same quarter last year. As a group, sell-side analysts anticipate that Merck & Co., Inc. will post 7.75 earnings per share for the current fiscal year.
Merck & Co., Inc. Company Profile
Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.
Featured Stories
- Five stocks we like better than Merck & Co., Inc.
- Airline Stocks – Top Airline Stocks to Buy Now
- 4 Reasons to Grab Shares of Grab Holdings Before 2024 Ends
- What is MarketRankā¢? How to Use it
- Super Micro Computer : AI Growth Potential vs. Investor Doubts
- Dividend Payout Ratio Calculator
- Instacart: Is it Time to Back Up the Cart on the Stock?
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.